Arch Therapeutics, Inc.: auditor change — Arch Therapeutics dismisses Baker Tilly, appoints Weinberg & Company as auditor

Arch Therapeutics, Inc.

Audit committee dismissed Baker Tilly effective Jan 9, 2024; appointed Weinberg & Company.
Baker Tilly's reports for FY2022 and FY2021 included a going concern explanatory paragraph.
No disagreements or reportable events between the company and Baker Tilly in relevant periods.
Baker Tilly's letter to SEC regarding this change is filed as Exhibit 16.1.

item 4.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Arch Therapeutics, Inc. engaged Weinberg & Company, P.A. as its auditor.

Action: engagement
Auditor: Weinberg & Company, P.A.

Exact text from the filing

On January 9, 2024, the Audit Committee approved the appointment of Weinberg & Company, P.A. (“Weinberg”) as the Company’s new independent registered public accounting firm, effective immediately.

View on SEC.gov

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Arch Therapeutics, Inc. dismissed Baker Tilly US, LLP as its auditor.

Action: dismissal
Auditor: Baker Tilly US, LLP
Successor: Weinberg & Company, P.A.

Exact text from the filing

On January 9, 2024, the Audit Committee of the Board of Directors (the “Audit Committee”) of Arch Therapeutics, Inc. (the “Company”) dismissed Baker Tilly US, LLP (“Baker Tilly”) as the Company’s independent registered public accounting firm, effectively immediately.

View on SEC.gov

Browse all auditor changes →

Source: SEC EDGAR

accession 0001437749-24-001286

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.